Edgen Stock·Mar 31 2026, 10:29Key Takeaways:
Ascentage Pharma reported a wider full-year loss of $177.7 million for 2025 as it ramped up spending on clinical trials and commercial launches for its core cancer therapies.
"2025 was a year of significant execution in advancing our mission to deliver innovative therapies to patients worldwide," Dr. Dajun Yang, Chairman and Chief Executive Officer of Ascentage Pharma, said in a statement.
The biopharmaceutical company's total revenue fell 41.5 percent to $82.1 million, primarily due to a lack of the intellectual property income that boosted 2024 results. However, product sales showed strong momentum, with Olverembatinib sales jumping 80.6 percent to $62.2 million and the newly launched Lisaftoclax adding $10.1 million in its first five months.
The increased loss reflects a strategic push, with research and development expenses climbing 20.1 percent to $162.7 million. With a strengthened cash position of $353.2 million from recent offerings, Ascentage is funding seven late-stage global trials for its two approved drugs, Olverembatinib and Lisaftoclax, targeting major cancer markets in the US and Europe.
The company is advancing three global Phase III trials for its third-generation tyrosine kinase inhibitor, Olverembatinib, in patients with chronic myeloid leukemia (CML) and other cancers. Two of these late-stage trials have been cleared by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Ascentage's second commercial product, the Bcl-2 inhibitor Lisaftoclax, is also in four global registrational Phase III trials for various blood cancers. The drug was approved and launched in China in July 2025 for chronic lymphocytic leukemia, and the company is actively pursuing its inclusion in the national reimbursement list to improve patient access.
The surge in product sales demonstrates growing market adoption in China, a crucial step for Ascentage's commercial viability. Investors will now be closely watching for top-line data from the multiple global Phase III trials, which represent the next major catalysts for the company's international expansion plans.
This article is for informational purposes only and does not constitute investment advice.
